Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy

Therapeutic Advances in Urology

Volumn 3, Issue 3, 2011, Pages 107-117

  Balar, Arjun ^a   Bajorin, Dean F ^b   Milowsky, Matthew I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

bladder cancer; bladder preservation; cystectomy; octogenarians; radiation therapy; transitional cell carcinoma; transurethral resection of bladder tumor; TURBT; urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; TRASTUZUMAB; VINBLASTINE;

BLADDER; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CYSTECTOMY; GERIATRIC ASSESSMENT; HUMAN; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; REVIEW; SURVIVAL TIME; TRANSURETHRAL RESECTION; TREATMENT RESPONSE;

EID: 80051728299     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287211407543     Document Type: Review

References (56)

1. Advanced Bladder Cancer Meta-analysis Collaboration. (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361: 1927–1934.
2. Azuma H. Inamoto T. Ibuki N. Ubai T. Kotake Y. Takahara K. (2011) Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer. Int J Oncol 38: 13–24.
3. Brannan W. Ochsner M.G. Fuselier H.A. Jr Landry G.R. (1978) Partial cystectomy in the treatment of transitional cell carcinoma of the bladder. J Urol 119: 213–215.
4. Capitanio U. Isbarn H. Shariat S.F. Jeldres C. Zini L. Saad F. (2009) Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysis. Urology 74: 858–864.
5. Chakravarti A. Winter K. Wu C.L. Kaufman D. Hammond E. Parliament M. (2005) Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62: 309–317.
6. Cole C.J. Pollack A. Zagars G.K. Dinney C.P. Swanson D.A. von Eschenbach A.C. (1995) Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 32: 331–340.
7. Cole D.J. Durrant K.R. Roberts J.T. Dawes P.J. Yosef H. Hopewell J.W. (1992) A pilot study of accelerated fractionation in the radiotherapy of invasive carcinoma of the bladder. Br J Radiol 65: 792–798.
8. Coppin C.M. Gospodarowicz M.K. James K. Tannock I.F. Zee B. Carson J. (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14: 2901–2907.
9. Coughlin C.T. Richmond R.C. (1989) Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Semin Oncol 16(4Suppl. 6): 31–43.
10. Dandekar N.P. Tongaonkar H.B. Dalal A.V. Kulkarni J.N. Kamat M.R. (1995) Partial cystectomy for invasive bladder cancer. J Surg Oncol 60: 24–29.
11. Danesi D.T. Arcangeli G. Cruciani E. Altavista P. Mecozzi A. Saracino B. (2004) Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer 101: 2540–2548.
12. De Neve W. Lybeert M.L. Goor C. Crommelin M.A. Ribot J.G. (1995) Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 36: 183–188.
13. deVere White R.W. Lara P.N. Jr. Goldman B. Tangen C.M. Smith D.C. Wood D.P. Jr (2009) A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol 181: 2476–2480. discussion 2480–2471.
14. Donat S.M. Siegrist T. Cronin A. Savage C. Milowsky M.I. Herr H.W. (2010) Radical cystectomy in octogenarians–does morbidity outweigh the potential survival benefits? J Urol 183: 2171–2177.
15. Fernando S.A. Sandler H.M. (2007) Multimodality bladder preservation therapy for muscle-invasive bladder tumors. Semin Oncol 34: 129–134.
16. Grossman H.B. Natale R.B. Tangen C.M. Speights V.O. Vogelzang N.J. Trump D.L. (2003) Neoadjuvant chemotherapy plus cystectomycompared with cystectomy alone for locallyadvanced bladder cancer. N Engl J Med 349: 859–866.
17. Hall R. (2002) Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol 21: Abstract 710.
18. Herman J.M. Smith D.C. Montie J. Hayman J.A. Sullivan M.A. Kent E. (2004) Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology 64: 69–73.
19. Herr H.W. (2001) Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19: 89–93.
20. Herr H.W. Bajorin D.F. Scher H.I. (1998) Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 16: 1298–1301.
21. Herr H.W. Faulkner J.R. Grossman H.B. Natale R.B. deVere White R. Sarosdy M.F. (2004) Surgical factors influence bladder cancer outcomes: acooperative group report. J Clin Oncol 22: 2781–2789.
22. Hollenbeck B.K. Miller D.C. Taub D. Dunn R.L. Underwood W. III Montie J.E. (2004) Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology 64: 292–297.
23. Holzbeierlein J.M. Lopez-Corona E. Bochner B.H. Herr H.W. Donat S.M. Russo P. (2004) Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 172: 878–881.
24. International Collaboration of Trialists. (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: arandomised controlled trial. Lancet 354: 533–540.
25. James N.D. Hussain S.A. Hall E. Jenkins P. Tremlett J. Rawlings C. (2010) Results of aphase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC)(BC2001 CRUK/01/004). J Clin Oncol 28: 346s–346s.
26. Jenkins B.J. Caulfield M.J. Fowler C.G. Badenoch D.F. Tiptaft R.C. Paris A.M. (1988) Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 62: 343–346.
27. Kachnic L.A. Kaufman D.S. Heney N.M. Althausen A.F. Griffin P.P. Zietman A.L. (1997) Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15: 1022–1029.
28. Kaneti J. (1986) Partial cystectomy in the management of bladder carcinoma. Eur Urol 12: 249–252.
29. Kassouf W. Swanson D. Kamat A.M. Leibovici D. Siefker-Radtke A. Munsell M.F. (2006) Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 175: 2058–2062.
30. Kaufman D.S. Winter K.A. Shipley W.U. Althausen A.F. Hug E.B. Toonkel L.M. (2008) Muscle-invading bladder cancer, RTOG Protocol 99-06: Initial report of a phase I/II trial of selective bladder-conservation employing TURBT, accelerated irrdiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy. 2005 ASCO Annual Meeting 23(No. 16S, Part I of II (June 1 Supplement): 4506–4506.
31. Kaufman D.S. Winter K.A. Shipley W.U. Heney N.M. Wallace H.J. III Toonkel L.M. (2009) Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73: 833–837.
32. Kent E. Sandler H. Montie J. Lee C. Herman J. Esper P. (2004) Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol 22: 2540–2545.
33. Kirkali Z. Chan T. Manoharan M. Algaba F. Busch C. Cheng L. (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66(6 Suppl. 1): 4–34.
34. Leibovici D. Kassouf W. Pisters L.L. Pettaway C.A. Wu X. Dinney C.P. (2007) Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology 70: 473–476.
35. Lichtman S.M. Boparai M.K. (2008) Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. Curr Treat Options Oncol 9: 191–203.
36. Luciani A. Ascione G. Bertuzzi C. Marussi D. Codeca C. Di Maria G. (2010) Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol 28: 2046–2050.
37. Mameghan H. Fisher R. Mameghan J. Brook S. (1995) Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 31: 247–254.
38. Oh K.S. Soto D.E. Smith D.C. Montie J.E. Lee C.T. Sandler H.M. (2009) Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 74: 511–517.
39. Pollack A. Zagars G.Z. (1996) Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin Urol Oncol 14: 86–95.
40. Rodel C. Grabenbauer G.G. Kuhn R. Papadopoulos T. Dunst J. Meyer M. (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20: 3061–3071.
41. A., Sell, A., Jakobsen, B., Nerstrom, B.L., Sorensen, K., Steven, H., Barlebo, Treatment of advanced bladder cancer category T2 T3 and T4a. Arandomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group, ScandJ Urol Nephrol Suppl, (1991), 138, 193-201
42. Shipley W.U. Cummings K.B. Coombs L.J. Hawkins I.R. Einstein A.B. Penick G. (1982) 4,000 RAD preoperative irradiation followed by prompt radical cystectomy for invasive bladder carcinoma: a prospective study of patient tolerance and pathologic downstaging. J Urol 127: 48–51.
43. Shipley W.U. Kaufman D.S. Zehr E. Heney N.M. Lane S.C. Thakral H.K. (2002) Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60: 62–67. discussion 67–68.
44. Shipley W.U. Winter K.A. Kaufman D.S. Lee W.R. Heney N.M. Tester W.R. (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16: 3576–3583.
45. Sischy B. Doggett R.L. Krall J.M. Taylor D.G. Sause W.T. Lipsett J.A. (1989) Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. JNatl Cancer Inst 81: 850–856.
46. Smaldone M.C. Jacobs B.L. Smaldone A.M. Hrebinko R.L. Jr (2008) Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology 72: 613–616.
47. Solsona E. Iborra I. Collado A. Rubio-Briones J. Casanova J. Calatrava A. (2010) Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 184: 475–480.
48. Stein J.P. Lieskovsky G. Cote R. Groshen S. Feng A.C. Boyd S. (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19: 666–675.
49. Sternberg C.N. Pansadoro V. Calabro F. Schnetzer S. Giannarelli D. Emiliozzi P. (2003) Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 97: 1644–1652.
50. Sweeney P. Kursh E.D. Resnick M.I. (1992) Partial cystectomy. Urol Clin North Am 19: 701–711.
51. The Department of Veterans Affairs Laryngeal Cancer Study Group. (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324: 1685–1690.
52. Tucci A. Ferrari S. Bottelli C. Borlenghi E. Drera M. Rossi G. (2009) A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 115: 4547–4553.
53. Varveris H. Delakas D. Anezinis P. Haldeopoulos D. Mazonakis M. Damilakis J. (1997) Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Anticancer Res 17: 4771–4780.
54. Whitmore W.F. Jr Batata M.A. Ghoneim M.A. Grabstald H. Unal A. (1977) Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol 118: 184–187.
55. Wu X.R. (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5: 713–725.
56. Yafi F.A. Cury F.L. Kassouf W. (2009) Organ-sparing strategies in the management of invasive bladder cancer. Expert Rev Anticancer Ther 9: 1765–1775.